Sichenzia Ross Friedman Ference LLP Represents Citius Pharmaceuticals Inc. in connection with its acquisition of LM Biosciences, Inc.
Press Release – New York, NY – March 8, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Citius in its acquisition of LM Biosciences, Inc. (“LMB”). LMB is a late-stage specialty pharmaceutical company focused on the development and commercialization of critical care products with a concentration of anti-infective drugs.
The acquisition was an all stock transaction and included a $3 million investment by Citius’ Chairman of the Board. The Sichenzia Ross Friedman Ference LLP was led by Partners Arthur Marcus, Gregory Sichenzia and associate Nazia Khan.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $2.3 Million Public Offering of Common Stock of Sigma Labs, Inc. - August 3, 2019
- Sichenzia Ross Ference LLP Ranked as a Top Issuer Counsel for 2019 Q2 - July 24, 2019
- Sichenzia Ross Ference LLP Represents ThinkEquity in $1.35 Million Underwritten Public Offering of ADSs of Immuron Limited - July 23, 2019